ADC Therapeutics SA
ADCT- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001771910
No open-market purchases or sales by ADC Therapeutics SA insiders were filed in the last 90 days; 113 institutions reported holding it in 13F filings for Q2 2026, worth $86.3M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding ADC Therapeutics SA changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 41 | 38 | −3 |
| Shares | 39.5M | 34.0M | −5.49M (−13.9%) |
| Value | $35.4M | $56.4M | +$21.0M (+59.3%) |
New holders (8)
Institutions that held ADC Therapeutics SA at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 101,260 | $168.1K | 0.00% |
| HRT Financial LP | 80,086 | $132.0K | 0.00% |
| DLK Investment Management, LLC | 33,155 | $55.0K | 0.03% |
| Susquehanna International Group, LLP | 20,689 | $34.3K | 0.00% |
| Saxony Capital Management, LLC | 20,623 | $34.2K | 0.05% |
| Commonwealth Equity Services, LLC | 19,852 | $33.0K | 0.00% |
| Lynx Capital Group Ltd | 15,000 | $24.9K | 0.02% |
| Northwestern Mutual Wealth Management Co | 100 | $166 | 0.00% |
Sold out (11)
Institutions that held ADC Therapeutics SA at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Sio Capital Management, LLC | 3,294,534 | $2.96M |
| Frazier Life Sciences Management, L.P. | 1,647,030 | $1.48M |
| AlphaCentric Advisors LLC | 1,068,468 | $958.4K |
| BlackRock Inc. | 529,890 | $475.3K |
| Nantahala Capital Management, LLC | 257,162 | $230.7K |
| Gsa Capital Partners LLP | 121,897 | $109.0K |
| ELCO Management Co., LLC | 21,532 | $19.3K |
| Gladius Capital Management LP | 19,752 | $17.7K |
| Cutler Group LP | 1,400 | $1.00K |
| US Bancorp | 300 | $269 |
| Cornerstone Planning Group LLC | 14 | $13 |